HPV vaccine prices need to come down, Nobel winner says
This article was originally published in Scrip
Executive Summary
Current vaccines for cervical cancer are priced too high in many markets, while expanded vaccination programmes against the human papillomavirus (HPV) would bring a number of benefits, the joint winner of last year's Nobel Prize in Physiology or Medicine has told Scrip.